Cargando…

Scientific Validation and Clinical Application of Lung Cancer Organoids

Lung cancer organoid (LCO) is a novel model of lung cancer that facilitates drug screening. However, the success rate of LCOs varies from 7% to 87%, and the culture medium compositions are markedly different. Airway organoid media can be used for LCO cultures, but this promotes the overgrowth of nor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dahye, Kim, Yoonjoo, Chung, Chaeuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616085/
https://www.ncbi.nlm.nih.gov/pubmed/34831235
http://dx.doi.org/10.3390/cells10113012
_version_ 1784604262692552704
author Lee, Dahye
Kim, Yoonjoo
Chung, Chaeuk
author_facet Lee, Dahye
Kim, Yoonjoo
Chung, Chaeuk
author_sort Lee, Dahye
collection PubMed
description Lung cancer organoid (LCO) is a novel model of lung cancer that facilitates drug screening. However, the success rate of LCOs varies from 7% to 87%, and the culture medium compositions are markedly different. Airway organoid media can be used for LCO cultures, but this promotes the overgrowth of normal cell organoids especially in LCOs from intrapulmonary lesions. Several modified media are specifically utilized for promoting the cancer cell’s growth. For culturing high-purity LCOs, cancer cells from metastatic lesions and malignant effusions are used. Recently, single-cell RNA sequencing has identified previously unknown cell populations in the lungs and lung cancer. This sequencing technology can be used to validate whether the LCO recapitulates the heterogeneity and functional hierarchy of the primary tumor. Several groups have attempted to culture LCOs with mesenchymal cells and immune cells to recapitulate the tumor microenvironment. Disease modeling using LCO provides novel insight into the pathophysiology of lung cancer and enables high-throughput screening for drug discovery and prognosis prediction. An LCO model would help to identify new concepts as a basis for lung cancer targeting by discovering innovative therapeutic targets.
format Online
Article
Text
id pubmed-8616085
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86160852021-11-26 Scientific Validation and Clinical Application of Lung Cancer Organoids Lee, Dahye Kim, Yoonjoo Chung, Chaeuk Cells Review Lung cancer organoid (LCO) is a novel model of lung cancer that facilitates drug screening. However, the success rate of LCOs varies from 7% to 87%, and the culture medium compositions are markedly different. Airway organoid media can be used for LCO cultures, but this promotes the overgrowth of normal cell organoids especially in LCOs from intrapulmonary lesions. Several modified media are specifically utilized for promoting the cancer cell’s growth. For culturing high-purity LCOs, cancer cells from metastatic lesions and malignant effusions are used. Recently, single-cell RNA sequencing has identified previously unknown cell populations in the lungs and lung cancer. This sequencing technology can be used to validate whether the LCO recapitulates the heterogeneity and functional hierarchy of the primary tumor. Several groups have attempted to culture LCOs with mesenchymal cells and immune cells to recapitulate the tumor microenvironment. Disease modeling using LCO provides novel insight into the pathophysiology of lung cancer and enables high-throughput screening for drug discovery and prognosis prediction. An LCO model would help to identify new concepts as a basis for lung cancer targeting by discovering innovative therapeutic targets. MDPI 2021-11-04 /pmc/articles/PMC8616085/ /pubmed/34831235 http://dx.doi.org/10.3390/cells10113012 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lee, Dahye
Kim, Yoonjoo
Chung, Chaeuk
Scientific Validation and Clinical Application of Lung Cancer Organoids
title Scientific Validation and Clinical Application of Lung Cancer Organoids
title_full Scientific Validation and Clinical Application of Lung Cancer Organoids
title_fullStr Scientific Validation and Clinical Application of Lung Cancer Organoids
title_full_unstemmed Scientific Validation and Clinical Application of Lung Cancer Organoids
title_short Scientific Validation and Clinical Application of Lung Cancer Organoids
title_sort scientific validation and clinical application of lung cancer organoids
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616085/
https://www.ncbi.nlm.nih.gov/pubmed/34831235
http://dx.doi.org/10.3390/cells10113012
work_keys_str_mv AT leedahye scientificvalidationandclinicalapplicationoflungcancerorganoids
AT kimyoonjoo scientificvalidationandclinicalapplicationoflungcancerorganoids
AT chungchaeuk scientificvalidationandclinicalapplicationoflungcancerorganoids